Worm.com

Guide to Spyware and AntiVirus Information

You are currently browsing the Worm.com weblog archives for the day Friday, June 27th, 2008.

 

Sponsors

Archive for June 27th, 2008

Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.

World Ophthalmic Pharmaceutical Drugs Market

http://www.reportlinker.com/p090570/World-Ophthalmic-Pharmaceutical-Drugs-Market.html

This report analyzes the worldwide markets for Opthalmic Pharmaceutical Drugs in US$ Million. The major therapeutic categories analyzed are Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 96 companies including many key and niche players worldwide such as Akorn, Inc., Alcon Eye Care, Inc., Allergan, Inc., Alimera Sciences, Inc., Bausch & Lomb, Inc., Genvec, Inc., GlaxoSmithKline Plc, Inspire Pharmaceuticals, Inc., ISTA Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Ophthalmics, Opko Health, Inc., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., QLT, Inc., Santen Pharmaceutical Co., and Santen Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

STANFORD, Calif. — Stanford University School of Medicine researchers received approximately $5.6 million on June 27 from the California Institute for Regenerative Medicine in awards designed to support the creation of new pluripotent human stem cell lines. All four of Stanford’s applicants were funded.

The researchers received multiyear grants of about $1.4 million each as part of CIRM’s newest round of awards. The awards support two types of research. One is the creation of new human embryonic stem cell (hESC) lines from excess or discarded early-stage human embryos created by in vitro fertilization. Another is the derivation of new pluripotent human stem cell lines either through a technique called somatic cell nuclear transfer or by modifying neonatal or adult cells to render them pluripotent. These "reprogrammed" cells are called induced pluripotent stem cells, or iPSCs. Grant reviewers gave special consideration to those types of research unlikely to receive federal funding.

Pluripotent stem cells can both renew themselves and become nearly any type of cells in the body. Unlike neonatal or adult cells, which have begun to specialize in certain types of cells or tissues, embryonic stem cells start with a genetic blank slate and are therefore considered to be the most reliable type of pluripotent cells for use in research and potential clinical applications.

However, the use of human embryos can present an ethical dilemma for many people. The creation of new pluripotent cells from neonatal or adult tissues, although likely to require additional modification, would circumvent many ethical issues. It may also allow the creation of personalized stem cell lines to treat specific individuals struggling to overcome injury or disease.

CIRM’s oversight committee granted 16 awards totaling $23 million out of about 50 applications from 38 non-profit institutions and 12 for-profit companies. With the latest round of grants, Stanford’s total funding from CIRM amounts to about $90 million, more than any other institution.

"CIRM continues to show its confidence in Stanford’s faculty and facilities," said Irving Weissman, MD, director of the Stanford Stem Cell Biology and Regenerative Medicine Institute. "We are extremely pleased and proud of the researchers who are the recipients of this latest round of funding."

Stanford researchers who were awarded the latest grants include:

* Renee Reijo Pera, PhD, director of the Human Embryonic Stem Cell Research and Education Center in Stanford’s stem cell institute. Unlike many adult cells, which require reprogramming through the introduction of genes to achieve pluripotency, recently derived, unmodified spermatogonial stem cells (SSCs) from mice have been shown to be very similar to embryonic stem cells. Reijo Pera plans to isolate matched pairs of SSCs and iPSCs from at least three men and to compare their molecular, genetic and developmental characteristics with those of recently derived hESC lines that are not eligible for federal funding. This approach will allow the first direct comparison of the research and clinical potential of two types of genetically identical pluripotent cell lines from the same men. Total funds awarded: $1.41 million.

* Michael Longaker, MD, MBA, deputy director of Stanford’s stem cell institute and director of the Program in Regenerative Medicine. Longaker and Eric Chiao, PhD, clinical instructor of obstetrics and gynecology, propose to compare the differentiation and functional potential of iPSCs with that of hESCs. Another arm of their studies involves the creation of disease-specific stem cell lines for Marfan Syndrome and Loeys-Dietz Syndrome, which affect both bone and cardiovascular development in those with the diseases. Total funds awarded: $1.42 million.

* Michele Calos, PhD, professor of genetics. Calos plans to investigate ways to reprogram adult cells to become pluripotent without the use of retroviruses. All currently available iPSCs were created with these viruses, which can cause cells to grow abnormally or become cancerous. These cell lines are therefore unsuitable for clinical use. Calos has developed a novel method for introducing the genes necessary for reprogramming into one defined chromosomal location that will not adversely affect the cells. She will use this method to create a variety of mouse and human iPSCs, which she will test for their ability to differentiate into a variety of tissues in vitro and to cure a genetic disorder in a mouse model. Total funds awarded: $1.41 million.

* Julie Baker, PhD, assistant professor of genetics. Baker plans to create more than 15 new hESC lines containing mutations that affect the ability of the cells to become neural tissues in the brain and spinal cord. Many of these mutations are associated with disorders that cause mental retardation in children, including Hurler syndrome, Fragile X syndrome, Tay-Sachs disease, and Canavan disease. New hESC lines of these disorders will allow researchers to observe their development in the laboratory and to test potential therapies without requiring them to rely on post-mortem tissue. Total funds awarded: $1.42 million.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

If the weather has you confused, think what it must be doing to your plants.

The cool, moist spring suddenly turned hot with a vengeance. In early June, plants thought that they had emigrated to Seattle, London or someplace besides our desert. Likewise, tomatoes, peppers and many warm-season flowers pouted as they waited for warmer temperatures to help them grow.

Of course, what happens in the garden is always weather-related. The trick is to determine what is happening and how it affects the plants. Is it a temporary problem or is it something that can have serious, life-threatening consequences for the plants?

Let’s start in the vegetable garden to check what is going on there.

The delineation here is between warm-season and cool-season vegetables. Any cool-season crops (peas, carrots, beets, lettuce and other vegetables) that were planted early liked the spring and probably produced good crops, providing they germinated in the cool, moist soils.

Some of these crops don’t like the heat. Temperatures in the 90s often cause them to bolt or flower and go to seed. Even if they don’t bolt, they usually turn tough and bitter, and the quality drops to the point they’re not worth eating. Cabbage heads often split.

Warm-season vegetables got off to a slow start. The first problem was getting the seed to germinate. Many warm-season crops will not germinate until soil temperatures reach 55 degrees, and many require soil temperatures of 75 degrees or more. That doesn’t happen when temperatures repeatedly drop into the 40s at night.

After getting warm-season crops to germinate, they still might not be happy. If you purchased transplants, they might have been sitting in the soil without growing much for several weeks. Now that it is warmer, they are finally starting to grow and hopefully should start producing soon.

One problem I have already seen hitting the tomatoes is curly top. This is a virus disease spread by the sugar beet leafhopper. The symptoms show as curled leaves that roll or turn upside down. The leaves turn yellow and the veins on the underside of the leaves are purple. If there is fruit, it ripens at whatever size it happens to be. There is no cure.

When the plants start to bloom, you might find another problem. All tree fruits and vegetables that produce a fruit have to be pollinated. While tomatoes, corn, peas, beans and several other crops are pollinated by the wind, most require bees to help the process.

For your fruit trees, either the bees were there or they weren’t, and it is too late to do anything about it now. The crops to watch are melons, squash, pumpkins and cucumbers. If you get blossoms but no fruit, you might do some hand pollinating by transferring pollen from the male blossoms to the female blossoms that have the little fruits attached.

Moving into the rest of the landscape, take a look at the trees. If you have London Plane or sycamore trees, they might be lacking their leaves. The culprit in this case is a fungus called sycamore anthracnose. The disease attacks the buds as they start to open. It then spreads into the wood. This causes the twigs to die and prevents leaf development.

Prevention is the key. Once the fungal diseases develop, it is too late to effectively control them. Fungicides are only effective if applied before the leaves unfold. Fortunately, these trees are resilient and will send out new, healthy leaves once the weather turns warm and dry.

Your aspen trees might show similar problems now — or even later — in the summer. Aspen leaf spot is another fungus that causes the leaves to develop dark spots that sometimes expand until they turn totally black. Any treatment after the spots appear is useless, so save your time and money.

Evergreen trees are making some homeowners nervous because as the new foliage emerges, the old needles look pretty rough. They survived drought and heat last year and look a little dry and discolored. Look at the new growth. If it is healthy and green, the trees are probably be fine.

Lawns are a whole different matter. Those who were complaining about mushrooms growing in their lawn a few weeks ago are now complaining about huge brown areas appearing like alien landing spots. The majority of brown spots are the result of improper watering. Check your sprinkler system, and also check the water penetration to make certain the water is going into the soil.

Fortunately, while most of our plants were happy for the moisture and cool air, most are also adapting to the normal summer temperatures. Nature has a way of helping them compensate and thrive in spite of our complaints. So get out and enjoy growing your garden!

Larry A. Sagers is the horticulture specialist, Utah State University Extension at Thanksgiving Point.

Copyright C 2008 Deseret News Publishing Co.
Provided by ProQuest Information and Learning Company. All rights Reserved.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

LONDON (AFP) — A star-studded cast of artists helped Nelson Mandela to celebrate his 90th birthday with a giant concert in London on Friday in support of his global AIDS campaign.

Queen, Amy Winehouse and Annie Lennox were among the performers at the Hyde Park gig for the former South African president’s 46664 campaign, which was being broadcast around the world.

Addressing the crowd, a visibly frail Mandela, who had to be helped to the podium on stage, said: “Where human beings are being oppressed, there is more work to be done. Our work is for freedom for all.

“It is time for new hands to lift the burdens. It is in your hands now. I thank you,” Mandela, who turns 90 on July 18, added.

Following an opening performance from Jivan Gasparyan, an Armenian duduk wooden flute master, US actor Will Smith introduced Anglo-Swedish rockers Razorlight. …


Read the full article with a Free Trial at MyWire.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

INDIANAPOLIS, June 27 /PRNewswire/ — WellPoint, Inc. announced today that, effective immediately, it will cover the rotavirus vaccine, Rotarix(R), designed to prevent a virus which causes vomiting and diarrhea in infants and children.

This decision to cover Rotarix(R), manufactured by GlaxoSmithKline, is based on formal recommendations announced this week by the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP).

ACIP recommended that Rotarix(R) be added to the list of recommended inoculations offered to infants. Rotarix(R) is a liquid given in a two-dose series to infants 6-24 weeks old.

According to the CDC, rotavirus infection is the leading cause of diarrhea in infants and young children, both in the United States and worldwide. Rotavirus disease causes about 410,000 physician office visits; 205,000-272,000 emergency department visits; 55,000-70,000 hospitalizations; and 20-60 deaths among children less than 5 years of age in the U.S. each year.

WellPoint’s immunization policy decisions are based on recommendations issued by ACIP and other nationally recognized organizations. ACIP is composed of 15 experts in fields associated with immunization who provide advice and guidance to the U.S. Department of Health and Human Services and CDC on the most effective means to prevent vaccine-preventable diseases.

The vaccine will be covered for infants whose benefit plans provide coverage for vaccines. Policyholders should confirm their specific benefits by calling the toll-free telephone number listed on their insurance card.

About WellPoint, Inc.

WellPoint, Inc. is the largest health benefits company in terms of medical membership in the United States. WellPoint is an independent licensee of the Blue Cross Blue Shield Association and serves its members as the Blue Cross licensee for California; the Blue Cross and Blue Shield licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (as the Blue Cross Blue Shield licensee in 10 New York City metropolitan and surrounding counties and as the Blue Cross or Blue Cross Blue Shield licensee in selected upstate counties only), Ohio, Virginia (excluding the northern Virginia suburbs of Washington, D.C.), Wisconsin; and through UniCare. Additional information about WellPoint is available at http://www.wellpoint.com/ .

CONTACT: Media, Jill Becher, +1-262-523-4764, or Investors, Michael Kleinman, +1-317-488-6713, both of WellPoint, Inc.

Web site: http://www.wellpoint.com/

COPYRIGHT 2008 PR Newswire Association LLC
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

*equestrianism

By Genevieve Murphy at Hickstead

Ellen Whitaker put aside her disappointing failure to secure Olympic selection by jumping her usual flying round with 17-year- old Cortaflex Kanselier, gaining a convincing victory in the Bunn Leisure Derby Salver here on the opening day of the British Jumping Derby meeting.

She finished a comfortable 4.53sec ahead of Irishman Damien Griffin, who was runner-up on Lisegan Clover Diamond. After collecting her first prize in the international arena, 22-year-old Whitaker hurried to an outside ring where she rode Shearwater Mikado to a double clear round in a preliminary contest for the six-year- old championship. “That’s my one for London 2012,” she said.

Whitaker’s hopes of contesting Beijing disappeared in Rotterdam last Friday when Locarno collected 24 faults in the first round of the Super League Nations Cup. The lapse could be explained by a mysterious skin rash (possibly a virus) but, since this contest had been scheduled as the stallion’s only Olympic trial, the excuse made no difference. “It was the most horrible week of my life,” Whitaker said of her time in the Netherlands. Though sound again after returning home, Locarno has not travelled here. If all goes well in today’s Derby Trial, Whitaker will be riding Ocalardo in Sunday’s DFS Derby.

Louise Pavitt, also aged 22, rode the Brendon Stud’s Unbelievable Darco to win the Derby Tankard, defeating two more British women - Jo Pay on Randi’s Gold and Gemma Paternoster on Osiris - in a three- horse jump-off.

Results, Digest, page 59

Copyright c 2008 Independent Newspapers UK Limited. All rights
owned or operated by The Independent.
Provided by ProQuest Information and Learning Company. All rights Reserved.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

ATHENS, Ohio — Diagnostic HYBRIDS has received funding through the Biomedical Research Commercialization Program (BRCP) to develop more sensitive and affordable assays for the monitoring of patients infected with Human Immunodeficiency Virus (HIV) and/or Hepatitis C Virus (HCV) and to produce vaccines against influenza virus. The BRCP is part of the Third Frontier Project, a push by Ohio lawmakers to bring biotechnology and related businesses into the state of Ohio.

The project and award bring together researchers from Diagnostic HYBRIDS, Case Western Reserve University, The Case Western Reserve/University Hospitals of Cleveland Center for AIDS Research, and Apath LLC, a St. Louis-based pharmaceutical development services company. The team will commercialize systems that monitor drug resistance in HIV, HCV, and Influenza infections and will aid in developing treatments and vaccines for these diseases.

"HIV/AIDS and Hepatitis C virus are two of the most devastating human pathogens of our time, infecting 40 and 180 million people respectively worldwide, and killing a combined 6 million people annually," said Miguel Quinones-Mateu, Ph.D., Senior Director of the HIV Program for Diagnostic HYBRIDS. "Influenza is another deadly disease that is part of the national emerging infectious agent preparedness program. Currently, influenza is largely responsible for 300,000 deaths per year, emerging influenza strains in the past have resulted in global pandemics, and we must not forget the constant threat of bird flu. Together, these three viruses cause more deaths than any other agent, disease, or disorder."

Quinones-Mateu added that "treatment monitoring and vaccine development involving these viral diseases represent a multibillion dollar market opportunity, and this BRCP award cements Ohio’s economic investment and commercialization role in it."

The researchers are using a yeast-based cloning technology first developed by Eric J. Arts, associate professor of medicine at Case Western Reserve University, to investigate drug resistance and vaccine development for HIV, HCV, and influenza. A world leader in studying HIV pathogenesis, and in collaboration with Diagnostic HYBRIDS since 2006, Dr. Arts and his research team have focused on HIV drug resistance testing. The methodology will first be commercialized for HIV. Future efforts will be directed towards cost-efficient ways to monitor drug resistance and assist in the characterization of new drugs and vaccines for HCV and influenza.

"We have been working hard for several years with Diagnostic HYBRIDS to get this technology to the point where it can be brought to market for the benefit of patients in Ohio, the US, and around the world," says Arts. "The funding from the BRCP grant will help us achieve that goal with greater speed. This is a great example of Ohio’s research and business worlds coming together for the greater good."

The yeast vector technology platform shows promise for commercialization in national and international markets, and will create additional employment opportunities in Cleveland, where Diagnostic HYBRIDS opened a research and development laboratory to serve the project in February 2008. The company’s global headquarters is located in Athens, Ohio.

"We are grateful to the Third Frontier Commission for their support of this key initiative," said David R. Scholl, Ph.D., Chairman, President & CEO of Diagnostic HYBRIDS. "Our goal has always been to participate in the development of a center of excellence for virology in Ohio. Through our long-term partnership with Case Western Reserve University, we have begun this effort, and the BRCP award will greatly enhance our ability to accomplish this goal in an accelerated fashion," Scholl added.

About Diagnostic HYBRIDS

Diagnostic HYBRIDS invents, develops, manufactures, and sells innovative diagnostic and analytical products for a wide range of viral respiratory diseases, herpes virus infections, and other specific viral and thyroid diseases. The company also develops and commercializes innovative and genetically engineered cell-based detection products for the pharmaceutical and biotechnology industry, with an initial focus on pharmacology assays and products that measure drug clearance and anti-viral interventions with drugs and vaccines. The company is certified to ISO 13485 standards and manufactures live continuous and primary cell cultures for clinical diagnostics and pharmacology assays from its headquarters in Athens, Ohio. Diagnostic HYBRIDS was named one of the 500 Fastest Growing Companies in America in 2004 and 2005 by Inc. Magazine. The company is a pillar member of BioOhio, a statewide organization of bioscience companies accelerating the bioscience and healthcare economy in Ohio. For more information, please visit www.dhiusa.com.

About Case Western Reserve University School of Medicine

Founded in 1843, Case Western Reserve University School of Medicine is the largest medical research institution in Ohio and 15th largest among the nation’s medical schools for research funding from the National Institutes of Health. Eleven Nobel Laureates have been affiliated with the school. The School of Medicine is recognized throughout the international medical community for outstanding achievements in teaching and in 2002, became the third medical school in history to receive a pre-eminent review from the national body responsible for accrediting the nation’s academic medical institutions. The School’s innovative and pioneering Western Reserve2 curriculum interweaves four themes–research and scholarship, clinical mastery, leadership, and civic professionalism–to prepare students for the practice of evidence-based medicine in the rapidly changing health care environment of the 21st century.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

SAN DIEGO — Aethlon Medical, Inc. (OTCBB:AEMD) disclosed today that it has been featured in a cover story published in Medical Device Daily. The story is accessible online at: www.aethlonmedical.com/pdfs/mdd062508.pdf

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier[R], a first-in-class medical device designed to treat infectious disease. The Hemopurifier[R] provides real-time therapeutic filtration of infectious viruses and immunosuppressive particles, and is positioned to address the treatment of drug and vaccine resistant viruses. Additionally, the device holds promise in cancer care, as research studies have verified the Hemopurifier[R] is able to capture immunosuppressive particles secreted by tumors. The Hemopurifier[R] is designed to act both as a stand-alone therapeutic, and as an adjunct treatment to enhance clinical benefit of established therapies. Pre-clinical studies conducted by researchers representing leading government and non-government health organizations both in the United States and abroad have documented the effectiveness of the Hemopurifier[R] in capturing from circulation the viruses that constitute pandemic threats, including H5N1 Avian Influenza (bird flu), and Dengue Hemorrhagic Fever (DHF) from circulation. The company is conducting studies to support the use of the Hemopurifier[R] as a broad-spectrum treatment countermeasure against bioterror threats, including Smallpox, and Ebola, Marburg, and Lassa hemorrhagic fever. Regulatory and commercialization initiatives in the United States are presently focused on bioterror threats, while international initiatives are directed toward naturally evolving pandemic threats, and chronic infectious disease conditions including the Human Immunodeficiency Virus (HIV) and Hepatitis-C (HCV). Aethlon demonstrated the safety of the Hemopurifier[R] in a 24-treatment human study at the Apollo Hospital in Delhi, India, and is currently conducting further human studies at the Fortis Hospital, also located in Delhi. The company has submitted an investigational device exemption (IDE) to the U.S. Food and Drug Administration (FDA) to advance the Hemopurifier([R])as a broad-spectrum treatment countermeasure against category "A" bioterror threats. Additional information regarding Aethlon Medical and its Hemopu